FP7H2020HORIZON
World Health Organization
- Country
- CHSwitzerland
- Defence projects
- 0
- Projects, all programmes
- 54
- As coordinator
- 1
- EU contribution (CORDIS)
- EUR 16,095,769
- Active
- 2008 to 2025
Projects
54 projects, newest first
| Project | Programme | Year | Role | EU contribution |
|---|---|---|---|---|
| COURAGE IN EUROPECOURAGE in Europe - COllaborative Research on AGEing in Europe | FP7 | 2009 | Participant | EUR 440,000 |
| SURESupporting the Use of Research Evidence (SURE) for Policy in African Health Systems | FP7 | 2009 | Participant | EUR 25,890 |
| INYVAXOptimisation of the development of Poverty-Related-Diseases (PRD) vaccines by a transversal approach, addressing common gaps and challenges | FP7 | 2009 | Participant | EUR 144,630 |
| PHARVATPlatform for the Harmonization of Vaccine Adjuvant Testing | FP7 | 2009 | Participant | EUR 100,000 |
| HEALTH PROMETHEUSHEALTH PROfessional Mobility in THe European Union Study | FP7 | 2009 | Participant | EUR 795,950 |
| BRIDGEScoping study of approaches to Brokering knowledge and Research Information to support the Development and Governance of health systems in Europe | FP7 | 2009 | Coordinator | EUR 790,997 |
| CHAINCollaborative HIV and Anti-HIV Drug Resistance Network | FP7 | 2009 | Participant | EUR 70,000 |
| MONITORING MEDICINESOptimizing drug safety monitoring to enhance patient safety and achieve better health outcomes | FP7 | 2009 | Participant | EUR 663,496 |
| ATOMEAccess to Opioid Medication in Europe | FP7 | 2009 | Participant | EUR 370,693 |
| CRIMALDDICoordination, rationalisation and integration of antimalarial drug discovery initiatives | FP7 | 2009 | Participant | EUR 58,650 |
| OPTIMALVACInitiative on Optimizing Malaria Vaccine Lab Assays Evaluation | FP7 | 2009 | Participant | EUR 180,000 |
| ENERGYEuropeaN Energy balance Research to prevent excessive weight Gain among Youth | FP7 | 2009 | Participant | EUR 40,495 |
| PENTA-LABNETPaediatric European Network Treatment AIDS Laboratory Network (PENTA LABNET) | FP7 | 2008 | Participant | EUR 20,200 |
| ARTEMIPTHE SAFETY PHARMACOLOGY OF ARTEMISININS WHEN USED TO REVERSE PATHOPHYSIOLOGY OF MALARIA IN PREGNANCY | FP7 | 2008 | Participant | EUR 46,080 |
The country is the one the source records for the organisation’s registration (its PIC), and each profile says what it rests on. Where the record contradicts itself (the address in one country, the site name and the VAT number in another) we follow the two that agree: the Spanish research council CSIC is shown under Spain although its address is recorded in Italy. A body with sites in several countries is shown under the first of them in alphabetical order, and its profile lists the others. Beyond that we do not guess.
Where this comes from
- CORDIS: EU research projects (Horizon Europe, Horizon 2020, FP7)Last read on . Licence: Commission Decision 2011/833/EU (reuse of Commission documents). Source: CORDIS, European Commission.Participants and amounts as the Commission's CORDIS database states them (reuse under Commission Decision 2011/833/EU).
EU contribution is the amount CORDIS's open data pays to the participant. For a participant with linked third parties it may include their share (the CORDIS page prints the net); an amount the data does not hold is left out, not counted as zero. EDF factsheets state none per participant, so EDF projects count as projects but add nothing to the amounts.
Organisation-level facts only: a name, a country, a role, an amount, a year. A participant is recognised by its PIC where the source gives one, otherwise by name; the page says which. How the data is built.
Names are as CORDIS and the EDF project factsheets publish them. We do not list an organisation whose name looks like a natural person’s. If this entry is you, or a business named after you, and you want it removed, write to the contact in the imprint; the privacy notice (sections 7 and 9) says how a request is handled.